[REVISION HISTORY]
Hims & Hers business expansion and market performance
1 recorded revision of this situation.
What changed
2026-11-18 23:49 UTC → 2026-11-19 18:03 UTC ·
added
removed
Hims & Hers has implemented several strategic expansions to its telehealth platform. The company expanded its subscriber benefits program to include 14 partners, offering discounts on products such as Tonal strength training systems and GrĂ¼ns gummies to support GLP-1 weight loss journeys. Additionally, In a significant expansion of the company launched direct-to-consumer wellness market, Hims & Hers and Noom announced the launch of peptide-based treatment services. Hims & Hers introduced its Peptides+ service, platform, which provides treatments including offers five initial treatments: Sermorelin, NAD+, Glutathione, Vitamin B12, and Glutathione L-Carnitine. These products are provided through licensed U.S. compounding pharmacies. pharmacies to support areas such as muscle growth, energy production, and anti-aging. The company acknowledged that more research is needed regarding the efficacy of these treatments. Most of these compounded peptides have not been approved by the Food and Drug Administration (FDA) and lack randomized controlled trials to confirm safety and efficacy in humans. This move follows a shift in federal oversight, as the Department of Health and Human Services has highlighted these drugs. Despite these developments and a 49% increase in third-quarter sales to $890.4 million, the company has faced stock volatility. Following its Q3 earnings report, Hims & Hers stock fell 17% after Q4 revenue guidance fell short of analyst expectations. The stock also saw a 2.93% decline during the period following the Peptides+ service launch.
Versions
- 2026-11-19 18:03 UTC Hims & Hers business expansion and market performance
- 2026-11-18 23:49 UTC Hims & Hers business expansion and market performance
Select a version to see what changed compared to the one before it.